RxDoctor Payments DataLook up a doctor →

Daniel Burdick, MD

Neurology · Kirkland, WANPI 1073750105

Payments from drug & device makers

$1,016,566in general payments, 2019–2025

Across 452 payments — averaging $2249.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$232K
  • AbbVie$220K
  • Sage Therapeutics, LLC$215K
  • Amneal Pharmaceuticals LLC$165K
  • Jazz Pharmaceuticals Inc.$84K
  • UCB SA$69K
  • plus $32K from 45 others
$961in research payments, 2019–2025

Across 12 payments — averaging $80.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$961

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck4$232,244
AbbVie(2 entities)71$219,881
Sage Therapeutics, LLC6$215,078
Amneal Pharmaceuticals LLC37$164,666
Jazz Pharmaceuticals Inc.16$83,951
UCB SA2$69,011
Astellas Pharma Global Development2$20,450
Acorda Therapeutics, Inc12$5,941
Teva Pharmaceuticals USA, Inc.44$834
Boston Scientific65$797
Novartis44$605
Acadia Pharmaceuticals Inc23$415
Merz Pharmaceuticals, LLC15$373
Bristol Myers Squibb18$208
Abbott2$184
Neurocrine Biosciences, Inc.7$148
TG Therapeutics, Inc.7$144
Sanofi6$125
CSL Behring5$110
UCB, Inc.4$105
Medtronic(2 entities)5$86
Lilly USA, LLC4$81
Sunovion Pharmaceuticals Inc.3$76
Eisai Inc.3$73
Merz North America, Inc.3$72
Amgen3$64
Octapharma USA, Inc.3$59
EMD Serono, Inc.3$59
Adamas Pharmaceuticals, Inc.3$59
MDD US Operations, LLC4$58
Argenx US, Inc.2$55
Johnson & Johnson2$54
SK Life Science, Inc.2$47
Avanir Pharmaceuticals, Inc.2$46
Neurelis, Inc.2$45
Vertical Pharmaceuticals, LLC2$43
GE HealthCare2$32
Ipsen Biopharmaceuticals, Inc1$29
Alnylam Pharmaceuticals Inc.1$28
Supernus Pharmaceuticals, Inc.1$25
Sanofi-aventis U.S. LLC1$23
E.r. Squibb & Sons, L.L.C.1$22
Insightec,inc1$22
Cycle Pharmaceuticals Inc1$21
AstraZeneca1$20
Biohaven Pharmaceuticals, Inc.1$19
Avion Pharmaceuticals1$18
Lundbeck LLC1$17
Banner Life Sciences, LLC1$15
Ultragenyx Pharmaceutical Inc.1$15
Genentech USA, Inc.1$13

How this compares

$1,016,566 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024
$83,643
Medicare patients
246
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Kirkland

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →